Valiant Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Valiant Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-228,983	Closed	-$12.9M	–	28
2023 Q2	$12.9M	Hold	228,983	–	–	1.21%	21
2023 Q1	$10.4M	Hold	228,983	–	–	0.82%	23
2022 Q4	$9.31M	Buy	228,983 +38,800	+20%	+$2.06M	1.43%	18
2022 Q3	$12.4M	Sell	190,183 -133,600	-41%	-$9.68M	1.24%	23
2022 Q2	$19.7M	Buy	323,783 +83,100	+35%	+$4.89M	1.98%	19
2022 Q1	$15.1M	Buy	240,683 +62,800	+35%	+$3.94M	1.73%	23
2021 Q4	$13.5M	Sell	177,883 -129,817	-42%	-$11.3M	1.63%	20
2021 Q3	$34.4M	Hold	307,700	–	–	3.24%	16
2021 Q2	$49.8M	Hold	307,700	–	–	3.74%	15
2021 Q1	$37.5M	Sell	307,700 -47,500	-13%	-$7.17M	1.45%	17
2020 Q4	$54.4M	Sell	355,200 -113,000	-24%	-$13.4M	2.38%	15
2020 Q3	$39.2M	Hold	468,200	–	–	2.04%	16
2020 Q2	$34.4M	Hold	468,200	–	–	3.42%	14
2020 Q1	$19.9M	Buy	468,200 +196,500	+72%	+$10.1M	2.06%	15
2019 Q4	$16.5M	Hold	271,700	–	–	1.93%	14
2019 Q3	$11.1M	Hold	271,700	–	–	0.61%	15
2019 Q2	$12.8M	Hold	271,700	–	–	1.04%	12
2019 Q1	$9.71M	Hold	271,700	–	–	0.87%	13
2018 Q4	$7.76M	Hold	271,700	–	–	0.73%	16
2018 Q3	$12.1M	Buy	+271,700	New	+$14.2M	1.07%	15

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Valiant Capital Management's CRSP Position: Q3 2023 in Review

Valiant Capital Management sold out of CRISPR Therapeutics (CRSP) in Q3 2023, closing a stake of 228,983 shares — an estimated $12.9M sold.

Valiant Capital Management first reported a position in CRSP in Q3 2018 and held it in 20 quarters. The position peaked at $54.4M in Q4 2020. 406 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

Valiant Capital Management reported no remaining CRISPR Therapeutics position as of Q3 2023 after selling out during the quarter.
Valiant Capital Management sold 228,983 CRISPR Therapeutics shares in Q3 2023, an estimated $12.9M.
Valiant Capital Management first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 20 quarters.
Valiant Capital Management's CRISPR Therapeutics position peaked at $54.4M in Q4 2020.
406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on Valiant Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.